• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Meyers Steve Lawrence claimed ownership of 152,728 shares (SEC Form 3)

    6/23/25 9:12:26 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Meyers Steve Lawrence

    (Last) (First) (Middle)
    C/O OCULAR THERAPEUTIX, INC.
    15 CROSBY DRIVE

    (Street)
    BEDFORD MA 01730

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/11/2025
    3. Issuer Name and Ticker or Trading Symbol
    OCULAR THERAPEUTIX, INC [ OCUL ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Commercial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 152,728(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) (2) 04/03/2032 Common Stock 45,000 $5.22 D
    Stock Option (Right to Buy) (3) 01/29/2033 Common Stock 100,000 $3.88 D
    Stock Option (Right to Buy) (4) 02/02/2034 Common Stock 145,000 $5.18 D
    Stock Option (Right to Buy) (5) 02/10/2035 Common Stock 222,000 $7.44 D
    Explanation of Responses:
    1. Includes 11,111 restricted stock units ("RSUs") remaining unvested pursuant to an award of 33,333 RSUs granted under the 2021 Stock Incentive Plan, as amended (the "Plan"), of Ocular Therapeutix, Inc. (the "Corporation") on January 30, 2023; 32,206 RSUs remaining unvested pursuant to an award of 48,309 RSUs granted under the Plan on February 3, 2024; and 74,000 RSUs remaining unvested pursuant to an award of 74,000 RSUs granted under the Plan on February 11, 2025. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
    2. This option was granted on April 4, 2022 and vests over four years, with 1/4 of the shares underlying the option having vested on March 15, 2023 and 1/48 of the shares vesting monthly thereafter.
    3. This option was granted on January 30, 2023 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.
    4. This option was granted on February 3, 2024 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.
    5. This option was granted on February 11, 2025 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Todd Anderman, Attorney-in-Fact for Steve Lawrence Meyers 06/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OCUL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    4/21/2023$18.00Outperform
    Robert W. Baird
    More analyst ratings

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

      BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's transformation to a retina-focused company.  Ocular Therapeutix Logo Designed with visual accessibility at its core, the logo is science-based, transformative, and joyful. The circular "O" represents the eye and the retina, while the full-spectrum color palette captures the vibrancy of human vision and the richness of life it enables. The treatment of the "X" represents the intersection of where the c

      6/26/25 1:54:08 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

      BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV. Clinical Trials at the Summit (CTS) 2025 Presentation Details: Company Presentation: Ocular TherapeutixSession: Diamond Sponsor TalksPresentation Date/Time: Friday, June 20, 2025, 7:55 – 8:05 PM PTPresenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study ResultsSession: Tyrosine Kinase

      6/16/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration

      Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjects SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026 These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD BEDFORD, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced that enrollment in the SOL-R registrational trial of its product candidate AXPA

      5/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocular Therapeutix® to Host Investor Day on June 13, 2024

      Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

      6/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2024 Results

      Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

      5/7/24 4:05:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

      Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

      4/16/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care